Background: Biologic therapies have improved outcomes in patients with severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), but reliable biomarkers predicting treatment response remain unclear. This systematic review and meta-analysis evaluated predictive biomarkers associated with response to biologic therapy. Methods: A systematic review of randomized controlled trials and observational studies evaluating biomarkers of response to biologic therapy in severe uncontrolled CRSwNP was conducted. Data were extracted using a standardized form, and quantitative synthesis was performed where appropriate. Risk of bias was assessed using the Cochrane risk-of-bias 2 tool and the Newcastle–Ottawa Scale. Results: The most frequently investigated predictors of treatment response included blood eosinophil count, serum IgE, tissue eosinophilia, FeNO, and clinical characteristics such as comorbid asthma and NSAID-exacerbated respiratory disease (NSAID-ERD). Biologic therapy consistently improved clinical outcomes; however, evidence supporting any single biomarker as a reliable predictor of treatment response remained inconsistent because of substantial heterogeneity across studies. Conclusions: Current evidence does not support a universally validated predictive biomarker for biologic response in severe uncontrolled CRSwNP. Further standardized, prospective studies are needed to enable personalized biologic therapy.